Fig. 2

Impact of guselkumab and adalimumab treatment on activated Th1 and activated Th17 cells. The proportion of A activated Th1 cells to CD3⁺ and CD4⁺ T cells (%) and B activated Th17 cells to CD3⁺ and CD4⁺ T cells (%). *p<0.05, by Wilcoxon signed-rank test